tbuckley/cabot-search huggingface dataset:
THU0127 IMMUNOGENICITY AND SAFETY OF 23-VALENT PNEUMOCOCCAL VACCINE IN PATIENTS WITH RHEUMATOID ARTHRITIS: RESULTS FROM 5-YEAR FOLLOW UP
Authors: Daria Bukhanova, Boris Belov, Galina Tarasova, Marina Sergeeva, Yury Muravyev, Galina Lukina, Natalia Demidova, Maria Cherkasova
Journal: Annals of the Rheumatic Diseases (2019)

<h3>Background</h3> In rheumatology, comorbid infections have significant impact on patients' morbidity, mortality and quality of life. Prevention of infections is an integral part of supervision of these patients. <h3>Objectives</h3> The aim of the study is to investigate immunogenicity and safety of 23-valent polysaccharide pneumococcal vaccine (PPV-23) in patients with rheumatoid arthritis (RA) in a five-years period. <h3>Methods</h3> The study included 79 RA patients with ≥2 recent episodes of respiratory tract infections (bronchitis, pneumonia). 52 RA pts were treated with methotrexate (MT), 14 – with leflunomide (Lef), 13– with TNF- α inhibitors + MT. One dose (0,5 ml) of PPV-23 was administered subcutaneously without discontinuing MT/Lef or 28-30 days prior to initiation of TNF- α inhibitors. Control visits were scheduled as follows: at baseline (Visit 1), and in 1, 3, and every year after immunization. 39 out of 110 pts were followed for 24 months, 23 pts – for 36 months, 23 pts – for 48 months, and 18 - for 60 months. Standard clinical examination and lab tests were performed at each visit. Levels of serum antibodies (AB) to Pneumococcal capsular polysaccharide were measured with VaccZymeTM PCP IgG 2 panels (The Binding Site Group Ltd, Birmingham, UK). Coefficient of post-immunization response (CPR) was determined for each patient as the ratio of AB levels at Visits II, III, IV, V, VI and VII to AB level at Visit I. <h3>Results</h3> 53 (67%) patients did not have any reactions to the vaccine, 26 (33%) patients indicated pain, swelling and hyperemia of the skin (diameter up to 2 cm) at the injection site of the vaccine, low-grade fever. These typical reactions following vaccination are completely regressed within days without any additional treatment. They were not associated with RA therapy and did not require changes in ist schemes. Pronounced positive immune reaction to PPV-23 was documented in all RA patients on different therapeutic regimens as significant AB incremental growth. Significantly high level of post-immunization response still persisted after 4 and 5 years of follow-up.The proportion of responders to PPV-23 after 5 years reached 73% among RA patients. (Table). No case of clinically or radiographically confirmed pneumonia was documented during the follow up period, although one case of interstitial viral pneumonia was registered in 6 month after immunization. Not a single vaccination-related RA exacerbation episode or new autoimmune phenomenon was documented during the follow-up. *p&lt;0,05 <h3>Conclusion</h3> Thus, all given prove the sufficient immunogenicity and safety of 23-valent pneumococcal vaccine in RA patients after 5 years of follow-up, getting different therapeutic regimens. <h3>Disclosure of Interests</h3> None declared
PTU-090 Circulating Level of End Product of Apoptosis Caspase-Cleaved Keratin 18 Reflects Clinical Severity in Acute on Chronic Liver Disease and Is A Potential Biomarker for Diagnosis and Therapeutic Monitoring
Authors: S Macdonald, P Bachtiger, R Sawhney, P Holland-Fischer, J MacNaughtan, R Mookerjee, R Jalan, F Andreola
Journal: Gut (2016)

<h3>Introduction</h3> Acute on Chronic Liver Failure (ACLF) is characterised by progressive multi-organ failure and an unacceptably high mortality. This distinguishes it clinically and prognostically from Acute Decompensation (AD) of cirrhosis. We have previously demonstrated elevated markers of apoptosis in a rat model of ACLF and a small cohort of human ACLF patients. The aim of this study is to measure plasma levels of caspase-cleaved keratin 18 (cK18), a product of apoptosis, in a well-characterised cohort of subjects with progressive degrees of liver injury, with the aim of confirming our observation of elevated apoptosis in decompensated liver disease and establishing the utility of cK18 as a biomarker of severity of liver injury. Additionally, the correlation of cK18 levels with prognostic clinical scores will be assessed. <h3>Methods</h3> 78 patients with acutely decompensated liver disease were enrolled and divided into AD (n = 25), ACLF1 (n = 25) and ACLF2 (n = 28) using the CLIF-C ACLF and AD scores. Additionally, 27 stable compensated cirrhotic patients (SC) and 12 healthy volunteers were recruited. Plasma cK18 levels were measured by enzyme linked immunosorbent assay (ELISA) using the M30 antibody for detection. Results were analysed using Prism 6 Software (GraphPad). As the data were not normally distributed, a non-parametric test (Mann-Whitney-Wilcoxon test) was used. Spearman rank test was used for correlation studies. <h3>Results</h3> cK18 levels rose progressively with the severity of liver injury (median values and interquartile range): healthy 100.5 U/L (IR 76.97–144.7), stable cirrhosis 155.5 U/L (IR 102.5–269.8), AD 341.9 U/L (IR 102.5–489.9), ACLF1 603.6 U/L (IR 342.4–1046) and ACLF2 1028 U/L (IR 513.6–2641), respectively). Statistically significant differences were observed between healthy controls vs SC (p = 0.0232), SC vs AD (p = 0.0054), AD vs ACLF1 and 2 (p = 0.0054 and 0.0006 respectively), ACLF1 and 2 (0.068) (Figure 1). Additionally, cK18 values correlated with model for end-stage liver disease (MELD) score, (r = 0.48, p &lt; 0.0001), MELD Sodium (r = 0.44, p = 0.0001), sepsis-related organ failure (SOFA) (r = 0.39, p = 0.0021) and Childs-Pugh (r = 0.2562, p = 0.0323) scores. <h3>Conclusion</h3> Our data clearly demonstrates a statistically significant, progressive increase in circulating cK18 and apoptosis with increasing clinical severity of decompensated liver disease. These values also correlated with major prognostic scores used in current practice. cK18 is therefore a promising biomarker of severity of liver injury and further studies are needed to assess its role both as a prognostic tool and in monitoring therapeutic response. <h3>Disclosure of Interest</h3> None Declared
Diagnostic Application of Immunophenotypic Analysis of Erythroid Dysplasia in Myelodysplastic Syndromes. a Report on Behalf of the European Leukemianet-IMDS-Flow Cytometry Working Group
Authors: Theresia M Westers, Eline MP Cremers, Uta Oelschlaegel, Ulrika Johansson, Peter Bettelheim, Birgit Witte, Matteo G Della Porta, Wolfgang Kern, Arjan van de Loosdrecht
Journal: Blood (2014)
AB0925 Serum Galectin-3 and TGF-Beta Levels in Patients with Sarcoidosis
Authors: S. Kobak, M. Akyildiz, A. Gokduman, T. Atabay, H. Vural
Journal: Annals of the Rheumatic Diseases (2016)

<h3>Background</h3> Sarcoidosis is a chronic granulomatous disease characterized by non-caseating granuloma formation. Galectin-3 is a multifunctional protein involved in many biological processes such as fibrosis, angiogenesis and immune activation. <h3>Objectives</h3> To determine the serum galectin-3 and transforming growth factor-beta (TGF-beta) levels in patients with sarcoidosis and to determine a possible correlation with clinical findings. <h3>Methods</h3> Forty-four biopsy proven sarcoidosis patients followed at a single center and age and sex matched 41 healthy volunteers were included in the study. Demographic, clinical, laboratory and radiological data were recorded in all patients. Serum galectin-3 and TGF-beta levels were measured by ELISA method. <h3>Results</h3> Among 44sarcoidosis patients 13 (29.5%) were male and 31 (70.5%) were female. Average patient age was 47.4 years, mean disease duration was 3.2year. Twenty-one (47.7%) patients had erythema nodosum, three (6.8%) had uveitis, 40 (90.9%) had arthralgia, 23 (52.3%) had ankle arthritis, 15 (34.1%) had enthesitis. Laboratory evaluation showed increased serum ACE level in 24 (54.5%) patients, increased serum calcium level in 11 (25%) patients, increased serum D3 level in 5 (11.4%) patients, increased ESR and CRP levels in 22 (50%) and 23 (52.3%) patients, respectively. Serum galectin-3 level were similar in the sarcoidosis patients and the control group (p=0.977). No relationship were found between serum galectin-3 level and clinical and laboratory findings (p&gt;0.05). Serum TGF-beta level were higher in patients with sarcoidosis compared with the control group (p=0.005). Serum TGF-beta level was associated only with enthesitis and arthralgia (p=0.006,p=0.02), while no correlation were detected with other disease features (p&gt;0.05). <h3>Conclusions</h3> We found high level of serum TGF-beta, but normal level of galectin-3 in patients with sarcoidosis. These findings suggest that TGF-beta play an important role in the pathogenesis of sarcoidosis. to, there is a need for new Multicenter prospective studies are needed to illuminate the possible relationship between serum galectin-3 and sarcoidosis. <h3>Disclosure of Interest</h3> None declared
OP0187 All-Cause and Specified Causes of Mortality in Systemic Lupus Erythematosus: Systematic Review and Meta-Analysis of Clinical Trials: Table 1
Authors: A. Souto, A. Castelo, J.R. Maneiro, E. Cervantes, A. Mera, J. Gomez-Reino
Journal: Annals of the Rheumatic Diseases (2016)

<h3>Background</h3> Systemic lupus erythematosus (SLE) is an autoimmune disease with a broad spectrum of clinical manifestations. Increased morbidity and mortality were observed despite early and aggressive treatment. A changing pattern of mortality has been observed recently. <h3>Objectives</h3> To summarize the incidence rate (IR) of all-cause and specified causes of mortality in SLE in clinical trials (CT). <h3>Methods</h3> A systematic review was performed by searching the Medline, Embase and Cochrane databases. The search strategy identified all synonyms of disease and was limited to CTs. Data from randomized CTs and open-label studies were combined to assess the IR of all-cause and specified causes of mortality using a random effects model. <h3>Results</h3> The search identified 2168 articles. After selection, 140 studies met the inclusion criteria (13,409 patients and 18,028.71 patients-year of exposure) and were included in the analysis. A total of 283 SLE patients died. IR of all-cause of mortality was 1.73 per 100 patients-year. IRs of specific causes are showed in the table. Stratified analysis showed higher IR for patients treated with higher dose of glucocorticoids (≥1 mg/kg/day of prednisone) [IR was 3.13 (2.15–4.28) vs 1.22 (0.92–1.55)] and for studies with lower percentage of women (less than 91%) [IR was 2.10 (1.49–2.81) vs 1.32 (0.99–1.70)]. Differences in the IR in trials reflect a bias by indication. <h3>Conclusions</h3> Most frequent causes of death are still infections and cardiovascular disease. High doses of glucocorticoids were associated with higher rates of mortality. <h3>Disclosure of Interest</h3> None declared
The Overexpression of Inactive Phosphorylated Raf-1 Kinase Inhibitory Protein (RKIP) in Multiple Myeloma (MM) Regulates the Resistance to Bortezomib-Induced Cytotoxicity: Reversal of Resistance by the PKC Inhibitor Bisindolylmalemide
Authors: Sara Huerta-Yepez, Stavroula Baritaki, Hong Liu, Karla MC Mendez-Maldonado, Manuel L Penichet, Mario I Vega, Otoniel Martinez-Maza, Haiming Chen, James R. Berenson, Devasis Chatterjee, Benjamin Bonavida
Journal: Blood (2011)
High-dimensional single-cell analysis reveals the immune signature of narcolepsy
Authors: Felix J. Hartmann, Raphaël Bernard-Valnet, Clémence Quériault, Dunja Mrdjen, Lukas M. Weber, Edoardo Galli, Carsten Krieg, Mark D. Robinson, Xuan-Hung Nguyen, Yves Dauvilliers, Roland S. Liblau, Burkhard Becher
Journal: The Journal of Experimental Medicine (2016)

Narcolepsy type 1 is a devastating neurological sleep disorder resulting from the destruction of orexin-producing neurons in the central nervous system (CNS). Despite its striking association with the HLA-DQB1*06:02 allele, the autoimmune etiology of narcolepsy has remained largely hypothetical. Here, we compared peripheral mononucleated cells from narcolepsy patients with HLA-DQB1*06:02-matched healthy controls using high-dimensional mass cytometry in combination with algorithm-guided data analysis. Narcolepsy patients displayed multifaceted immune activation in CD4+ and CD8+ T cells dominated by elevated levels of B cell-supporting cytokines. Additionally, T cells from narcolepsy patients showed increased production of the proinflammatory cytokines IL-2 and TNF. Although it remains to be established whether these changes are primary to an autoimmune process in narcolepsy or secondary to orexin deficiency, these findings are indicative of inflammatory processes in the pathogenesis of this enigmatic disease.
Long Term Outcome of Chronic Phase Chronic Myeloid Leukemia (CP CML) Patients (pts) from the French Spirit Study Comparing Imatinib (IM) 400 Mg to Higher Dose Imatinib or Combination with Peg-interferonα2a (PegIFN) or Cytarabine (Ara-C) : A Trial of the FI LMC (France intergroupe de la leucemie myéloïde chronique)
Authors: Francois Guilhot, Francoise Rigal-Huguet, Joelle Guilhot, Agnès Guerci-Bresler, Franck E. Nicolini, Frédéric Maloisel, Delphine Rea, Valerie Coiteux, Martine Gardembas, Anne Vekhoff, Eric Jourdan, Laurence Legros, Martine Escoffre-Barbe, Philippe Rousselot, Claude Preudhomme, Francois-Xavier Mahon
Journal: Blood (2014)
Prognostic Impact of Cytogenetic Abnormalities in Elderly Patients with Acute Myeloid Leukemia (AML) Enrolled in the ALFA-9803 Trial.
Authors: Christine Terré, Claude Gardin, Nathalie Gachard, Isabelle Tigaud, François Désangles, Christian Bastard, Odile Maarek, Jean-Luc Lai, Alain Bernheim, Christine Perot, Florence Nguyen-Khac, Virginie Eclache, Ghislaine Plessis, Pascal Turlure, Xavier Thomas, Thierry de Revel, Pierre Fenaux, Hervé Dombret
Journal: Blood (2007)
AB0751 The Dependence of Osteoarthritis Progression from Glycemic Control in Patients with Diabetes
Authors: E. Trifonova, O. Sazonova, E. Zonova
Journal: Annals of the Rheumatic Diseases (2016)

<h3>Background</h3> The influence of type 2 diabetes mellitus (T2DM) on development and progression of osteoarthritis (OA) has been proved. However, there is a lack of data from more detailed researches in such category of patients. <h3>Objectives</h3> To estimate the proinflammatory serum cytokine levels and the clinical features in patients with knee OA and T2DM depending on glycemic control. <h3>Methods</h3> Patients (n=45) who had bilateral knee OA according to ACR criteria and T2DM were divided into two groups according to the compensation degree T2DM taking into account parameters of glycated hemoglobin concentrations (HbA1c) which were assessed using liquid chromatography. Blood glucose level was also estimated. Group 1 (n=26) had control T2DM. Group 2 (n=19) had no control T2DM. All patients were comparable by age, sex and duration of OA. Serum cytokine levels (IL-1b, IL-6, IL-10, IL-18), NO, and adypokines (adiponectin, leptin) using ELISA were assessed. Intensity of pain, general health, stiffness, physical functions were measured by visual analog scale (VAS),Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC), Knee injury and Osteoarthritis Outcome Score – (KOOS) and short form 36 (SF-36). U-Mann-Whitney test was applied to detect differences between groups. Correlation was assessed using Spearman correlation coefficient (rs). <h3>Results</h3> No significant difference has been found in parameters reflecting the functional disorders. Serum cytokines levels also were not different between the studied groups. Correlation analysis identified the relationships between clinical parameters and cytokines in OA patients with control and non-control T2DM. Certain data are presented (Table). <h3>Conclusions</h3> The results show that depending on the glycemic control may change clinical and immunology parameters of OA in patients with T2DM, especially in group with non-control T2DM. These data should be verified by larger studies and may be useful for the development of a personalized approach to patients with comorbid disorders such as OA and T2DM in future. <h3>References</h3> Piva S. R. et al. Links Between Osteoarthritis and Diabetes: Implications for Management from a Physical Activity Perspective //Clinics in geriatric medicine 2015 Louati K. et al. Association between diabetes mellitus and osteoarthritis: systematic literature review and meta-analysis //RMD open 2015 Esposito K. et al. Inflammatory cytokine concentrations are acutely increased by hyperglycemia in humans role of oxidative stress //Circulation 2002 Verzijl N. et al. Crosslinking by advanced glycation end products increases the stiffness of the collagen network in human articular cartilage: a possible mechanism through which age is a risk factor for osteoarthritis //Arthritis &amp; Rheumatism 2002 <h3>Disclosure of Interest</h3> None declared
Major Shrinking of Residual Tumor Cell Burden and Achievement of Molecular Remissions in Myeloma Patients Undergoing Post-Trasplant Consolidation with Bortezomib, Thalidomide and Dexamethasone: A Qualitative and Quantitative PCR Study
Authors: Marco Ladetto, Gloria Pagliano, Simone Ferrero, Federica Cavallo, Daniela Drandi, Michela Boi, Loredana Santo, Patrizia Pregno, Mariella Grasso, Anna Marina Liberati, Tommaso Caravita, Francesco Pisani, Claudia Crippa, Vincenzo Callea, Antonietta Falcone, Sergio Morandi, Mario Boccadoro, Antonio Palumbo
Journal: Blood (2008)
Platelets Recovery and Transfusion Needs after Reduced Intensity Conditioning (RIC) Allogeneic Stem Cell Transplantation (allo-SCT).
Authors: Mohamad Mohty, Martin Ferrando, Patrick Ladaique, Catherine Faucher, Sabine Furst, Norbert Vey, Anne-Marie Stoppa, Diane Coso, Frederic Viret, Gwenaelle Gravis, Jean-Albert Gastaut, Didier Blaise
Journal: Blood (2005)
P1247 : Unexpected high prevalence of HCV-viraemia (HCVRNA+) in the emergency department (ED) of a London hospital - should we be screening for HCV in ED attendees?
Authors: C. Orkin, E. Leach, S. Flanagan, E. Wallis, G.R. Foster, M. Ruf, C.Y. Tong
Journal: Journal of Hepatology (2015)
MAPK Signaling Cascades Mediate Distinct Glucocorticoid Resistance Mechanisms in Pediatric B-Precursor ALL
Authors: Courtney L Jones, Christy M Gearheart, Susan Fosmire, Cristina Delgado-Martin, Faye Pais, Jinhua Wang, Teena Bhatla, Danielle S Bitterman, Simone R de Rijk, Wallace Bourgeois, Smita C. Dandekar, Elizabeth A. Raetz, Michelle L. Hermiston, Michael J Garabedian, Christopher C. Porter, William L. Carroll
Journal: Blood (2014)
Arbitrary classification of hospital policy regarding open and locked doors – Authors' reply
Authors: Christian G Huber, Andres R Schneeberger, Eva Kowalinski, Daniela Fröhlich, Stefanie von Felten, Marc Walter, Martin Zinkler, Karl Beine, Andreas Heinz, Stefan Borgwardt, Undine E Lang
Journal: The Lancet Psychiatry (2016)
SAT0499 Septic Arthritis in Rheumatology: Management and Evolution over The Past 50 Years. About 374 Cases
Authors: R. Leroy, N. Segaud, H. Migaud, E. Senneville, B. Cortet, R.-M. Flipo
Journal: Annals of the Rheumatic Diseases (2016)

<h3>Background</h3> Septic arthritis is a multidisciplinary emergency which poses diagnostic problems due to the lack of biological and clinical specificity, and variable treatment modalities in the absence of formal consensus. <h3>Objectives</h3> The objective of this study was to describe epidemiology, management and evolution of rheumatologic septic arthritis over the past 50 years. <h3>Methods</h3> This epidemiological, retrospective, observational, single-center study, included patients hospitalized between 1997 and 2014 in one Rheumatology Department of a University Hospital, for septic peripheral arthritis of native joint. The diagnosis was determined according to Newman9s criteria. After a first descriptive part, we tried to determine associated factors for joint morbidity (define by the use of a non-sparing surgery or functional sequelae) and mortality after a follow-up of 1 year. Finally, we compared the results with a previous study, conducted in the same Department between 1966 and 1993 over 176 cases. <h3>Results</h3> On the 1997–2014 period, 198 patients were included corresponding to an annual incidence of 11 cases. The average age of patients was 56 years, with 57% men. Main comorbidities were arthropathy (37%), neoplasia (18%) and diabetes (17%). The most common presentation was monoarthritis (88%), of the knee (32%), caused by Staphylococcus aureus (56%). Nine percent of patients had received prior intra articular intervention. We noted 15% of arthritis with no identified pathogen. Endocarditis was found in 6% of patients. The support was multidisciplinary particularly between 2006 and 2014, with an increase of cooperation with bacteriologist (15% of cases between 1997–2005 versus 67% between 2006 and 2014, p&lt;0.0001), and a decrease in antibiotic duration (97.1 days versus 75.5 days, p=0.002). The surgical treatment was required in 33% of cases. The death rate at 1 year was 6% and the joint morbidity rate was 20%. Mortality risk factors have been identified (endocarditis OR =12.6 [2.0 to 81.4], p=0.008); MRSA OR =13.8 [1.9 to 100.6], p=0.009). Patients receiving corticosteroids had an excess risk of joint morbidity (OR =3.0 [1.0 to 8.7], p=0.04). In comparison with the previous study, there were more comorbidities (p&lt;0.01 for diabetes, neoplasia, rheumatoid arthritis), more bacterial identification and surgical care (p&lt;0.01). Iatrogenic origin and mortality remain stable. <h3>Conclusions</h3> In the absence of formal recommendations, multidisciplinary cooperation could impact directly on the diagnostic and therapeutic management of septic arthritis. The management seems better than in the 60–909s period, with no change in mortality. Infective endocarditis appears to be an important risk factor for mortality and its research should be systematic. <h3>Disclosure of Interest</h3> None declared
P2.05: The Synthetic Peptide CIGB-300 Inhibits NF-κB Translocation Affecting the Survival and Chemoresistance of NSCLC Cell Lines
Authors: Stéfano Cirigliano, María I. Díaz Bessone, Carolina Flumian, Damián Berardi, Silvio Perea, Elisa Bal De Kier Joffé, Hernán Farina, Laura Todaro, Alejandro Urtreger
Journal: Journal of Thoracic Oncology (2016)
Phase I/II Study of Marrow Infiltrating Lymphocytes (MILs) Generates Measurable Myeloma-Specific Immunity in the Autologous Stem Cell Transplant (SCT) Setting
Authors: Kimberly Noonan, Carol A. Huff, Janice M Davis Sproul, Mario Victor M Lemas, Lakshmi Rudraraju, Leo Luznik, Jonathan Powell, Javier Bolaños-Meade, Jeffrey Bitzan, Susan Fiorino, William Matsui, Richard J. Jones, Ivan M. Borrello
Journal: Blood (2011)
Safety and Efficacy of Low-Molecular-Weight Heparin in Pregnant Women at Increased Risk of Venous Thromboembolism: A Prospective Stratified Multicentre Trial.
Authors: Rupert M. Bauersachs, Joachim Dudenhausen, Andree Faridi, Thorsten Fischer, Samson Fung, Ulrich Geisen, Job Harenberg, Eberhard Herchenhan, Franz Keller, Bettina Kemkes-Matthes, Helmut Schinzel, Michael Spannagl, Christian J. Thaler
Journal: Blood (2006)